Lead Product(s) : ASC50
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascletis’ IL-17 Inhibitor ASC50 IND Cleared by FDA for Psoriasis Study
Details : ASC50 is an oral small molecule inhibitor of IL-17, an important biologically and commercially validated target for multiple autoimmune and inflammatory diseases, including psoriasis.
Product Name : ASC50
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2025
Lead Product(s) : ASC50
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PHT-776
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Photys Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Photys, Polymed Sign Exclusive Deal for Phase 1-Ready IRAK4 Degrader Development
Details : Under the agreement, Polymed has granted Photys an exclusive global license to develop, and commercialize HPB-143 (PHT-776) for treating atopic dermatitis.
Product Name : HPB-143
Product Type : PROTACs
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : PHT-776
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Photys Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : FZ007-119
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fermion's TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA
Details : FZ007-119 is a third-generation JAK inhibitor targeting TYK2 JH2. It's IND application is approved after preclinical studies for plaque psoriasis, inflammatory bowel disease & rheumatoid arthritis
Product Name : FZ007-119
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2024
Lead Product(s) : FZ007-119
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OQL025
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OnQuality Gets FDA Clearance for IND Application Of OQL025 for Acneiform Rash
Details : OQL025 is a first-in disease topical agent to treat moderate to severe acneiform rash in patients receiving EGFR inhibitors.
Product Name : OQL025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : OQL025
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1.
Product Name : AC-201
Product Type : Microorganism
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OQL036
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OnQuality Announces FDA Clearance of IND Application for OQL036
Details : OQL036 is a novel topical agent that locally alleviates the toxicities induced by capecitabine metabolites, and reduces the inflammation associated with capecitabine-induced hand-foot syndrome (HFS).
Product Name : OQL036
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : OQL036
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ICP-488
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China
Details : ICP-488 is a potent and selective TYK2 allosteric inhibitor that, by binding the JH2 domain, blocks the signal transduction of IL-23, IL-12, type 1 IFN and another inflammatory cytokine, thereby inhibiting the pathological process of autoimmune and infla...
Product Name : ICP-488
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : ICP-488
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China
Details : LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple cytokine-induced signaling pathways in vitro and in vivo. LNK01004 is tissue-restricted inhibitor that can potentially prevent safety issues caused by systemic drug exposure.
Product Name : LNK01004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : LNK01004
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy...
Product Name : KX-826
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GT20029
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial is a randomized, double-blind, vehicle-controlled, parallel-group, dose-escalationstudy in subjects to evaluate the safety, tolerability, and pharmacokinetics of GT20029 following topical single and multiple ascending dose administration.
Product Name : GT20029
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2021
Lead Product(s) : GT20029
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable